Coherus BioSciences Stock Price

0.59 (8.15%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 826,628
Bid Price 7.83
Ask Price 9.96
News -
Day High 7.87


52 Week Range


Day Low 7.12
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Coherus BioSciences Inc CHRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.59 8.15% 7.83 20:00:00
Open Price Low Price High Price Close Price Prev Close
7.21 7.12 7.87 7.83 7.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,130 826,628 $ 7.58 $ 6,265,872 - 5.60 - 19.32
Last Trade Time Type Quantity Stock Price Currency
16:05:31 average 300 $ 7.83 USD


Draw Mode:

Coherus BioSciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 606.22M 77.42M 61.14M $ 326.55M $ -230.61M -3.85 -2.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 177.99k 1.60%

more financials information »

Coherus BioSciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CHRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.487.877.107.45896,2310.354.68%
1 Month7.447.935.606.851,113,1380.395.24%
3 Months12.5112.935.608.141,070,677-4.68-37.41%
6 Months16.0916.485.6010.38966,861-8.26-51.34%
1 Year13.7719.325.6012.74805,094-5.94-43.14%
3 Years22.3123.915.6016.411,023,051-14.48-64.9%
5 Years14.4523.915.6015.64890,941-6.62-45.81%

Coherus BioSciences Description

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Your Recent History
Coherus Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.